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ABSTRACT
Background: Type 2 diabetes mellitus (T2DM) is a multifactorial disease where both
genetic and environmental factors contribute to its pathogenesis. The PvuII and
XbaI polymorphisms of the estrogen receptor 1 (ESR1) gene have been variably
associated with T2DM in several populations. This association has not been studied
in the Palestinian population. Therefore, the aim of this study was to investigate the
association between the PvuII and XbaI variants in the ESR1 and T2DM and its
related metabolic traits among Palestinian women.
Methods: This case–control study included 102 T2DM and 112 controls in which
PvuII and XbaI variants of the ESR1 gene were genotyped using amplicon based next
generation sequencing (NGS).
Results: Allele frequencies of both PvuII and XbaI variants were not signiﬁcantly
different between patients and control subjects (P > 0.05). In logestic regression
analysis adjusted for age and BMI, the ESR1 PvuII variant was associated with risk of
T2DM in three genotypic models (P < 0.025) but the strongest association was
observed under over-dominant model (TT+CC vs. TC) (OR = 2.32, CI [1.18–4.55]
adjusted P = 0.013). A similar but non-signiﬁcant trend was also observed for the
ESR1 XbaI variant under the over-dominant model (AA+GG vs. AG) (OR = 2.03,
CI [1.05–3.95]; adjusted P = 0.035). The frequencies of the four haplotypes
(TA, CG, CA, TG) were not signiﬁcantly different in the T2DM patients compared
with control group (P > 0.025). Among diabetic group, an inverse trend with risk
of cardio vascular diseases was shown in carriers of CG haplotype compared to those
with TA haplotype (OR = 0.28, CI [0.09–0.90]; adjusted P = 0.035). Further, stratiﬁed
analyses based on ESR1 PvuII and XbaI genotypes revealed no evidence for
association with lipid levels (TC, TG, HDL, LDL).
Conclusions: This is the ﬁrst Palestinian study to conclude that ESR1 PuvII and
XbaI variants may contribute to diabetes susceptibility in Palestinian women.
Identiﬁcation of genetic risk markers can be used in deﬁning high risk subjects and
in prevention trials.
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INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a multifactorial disease that caused by a complex
combination of genetic and environmental factors. Identiﬁcation of genetic polymorphisms
associated with diabetes may lead to prediction of disease development and prevention
of its vascular complications (Slominski et al., 2018). Recently, several reports have revealed
the role of estradiol in regulating energy metabolism (Hevener et al., 2018). It was evident that
estrogens increase hepatic insulin sensitivity, stimulate insulin synthesis in islets of
Langerhans, prevent β-cell apoptosis and improve insulin action in skeletal muscles
(Meyer et al., 2011).
Estrogen exerts its physiological functions through the estrogen receptors (ESR1, ESR2,
and a G-protein coupled cell surface receptor) and might prevent menopause syndrome,
cardio vascular diseases (CVD) and diabetes (Gupte, Pownall & Hamilton, 2015).
Estrogen receptor 1 (ESR1) is broadly expressed in adipose tissue, skeletal muscle, liver,
and immune cells. It is a ligand-activated transcription factor that regulates a large number
of genes in diverse target tissues (Hevener et al., 2018). Animal studies reported that
male and female ESR1 gene knockout mice developed features of the metabolic syndrome
(MetS) including obesity caused by impaired fatty acid oxidation, glucose intolerance, and
impaired insulin sensitivity, thus revealed the critical role of ESR1 in metabolic
homeostasis (Heine et al., 2000; Ribas et al., 2010).
The ESR1 gene, which encompasses 140 kb of DNA, is found on chromosomes 6q25.1.
It is a highly polymorphic gene containing more than 1,600 single nucleotide
polymorphisms (SNPs). Two SNPs in ESR1, both located in the ﬁrst intron, PvuII
(rs2234693) and XbaI (rs9340799), are the most extensively investigated variants and
reported to be associated with T2DM (Huang et al., 2006; Mohammadi et al., 2013),
MetS (Zhao et al., 2018), and other diseases (Onland-Moret et al., 2005; Silva et al., 2010;
Weng et al., 2015). These polymorphisms might interfere with the estrogen effect by
altering ESR1 gene expression via altering the binding of its own transcription factors
(Gomes-Rochette et al., 2017). Diabetes and obesity had reached an alarming rate among
Palestinians especially among refugees (El Kishawi et al., 2014; Shahin, Kapur & Seita,
2015). In 2015, the Palestinian Ministry of Health reported that cardiovascular diseases
were the leading cause of death and diabetes mellitus was the fourth cause of death among
Palestinians (Palestinian Ministry of Health, 2015). A recent study conducted on three
refugee camps in the West Bank, revealed that the overall prevalence of obesity and
overweight was 63.1% (for obesity: 42% in women and 29.2% in men; overweight 25.8%
and 28.9% in women and men; respectively). The prevalence of MetS among obese and
overweight adults was 69.4% with no gender-based differences (Damiri et al., 2018). Obese
and overweight individuals are at high risk of both cardiovascular diseases and T2DM
(Alberti & Zimmet, 1998). Estrogen deﬁciency is an important obesity-triggering factor
which enhances metabolic dysfunction and thus predisposing to T2DM and cardiovascular
diseases among menopausal women (Lizcano & Guzman, 2014). A meta-analysis study
Ereqat et al. (2019), PeerJ, DOI 10.7717/peerj.7164 2/15
investigating the new-onset of T2DM in post-menopausal women following estrogen
replacement therapy revealed a 30% lower relative risk [RR 0.7 (CI [0.6–0.9])] of diabetes
compared with placebo (Salpeter et al., 2006). However, the use of estrogen to prevent
chronic diseases is still challenging and controversial (Bolton, 2016).
As the ESR1 gene is a potential candidate gene for susceptibility to T2DM, we
hypothesized that the ESR1 variants (PvuII and XbaI) might be associated with T2DM,
diabetic complications and related metabolic traits in Palestinian diabetic women.
MATERIALS AND METHODS
Study design and participants
This case control study includes 214 Palestinian women (102 with T2DM and 112
non-diabetic controls). All participants were unrelated, aged >40 years and selected within
the period of 2016–2017 from the United Nations Relief and Works Agency for Palestine
Refugees clinics (Hebron and Ramallah, Palestine). Diagnosis of T2DM was based on
World Health Organization criteria (fasting plasma glucose  126 mg/dl and/or currently
on treatment for diabetes) (Kumar et al., 2016). The diagnosis of T2DM was conﬁrmed
based on patients’ medical records reporting initial diagnosis of diabetes mellitus after
age of 40, receiving oral hypoglycemic agents without insulin for at least 1 year after
initial diagnosis, and currently on treatment for diabetes. Patients with probable type 1
diabetes who received continuous insulin therapy since diagnosis were excluded. The
anthropometric measurements were collected from their medical records using a
standard questionnaire that included age, age at diagnosis, sex, family history, diabetic
complications, and medication for diabetes. BMI was calculated as kilograms divided by
the square of height in meters. Blood pressure was measured in sitting position, on the left
arm, after a 5-min rest by a health clinic worker, with a mercury sphygmomanometer.
Blood samples (ﬁve ml) after a 12-h minimum fast was collected in EDTA tubes for
biochemical tests as described in our previous work (Sabarneh et al., 2018). Plasma
glucose, cholesterol, HDL cholesterol, and triglyceride were determined using standard
methods of commercial kits (Human, Wiesbaden, Germany). Low-density lipoprotein
(LDL) cholesterol was calculated based on the Friedewald formula. The control group was
selected from individuals who came to the same clinic for an annual heath check-up,
they were eligible to be included if they had no prior diagnosis for T2DM, no family
history in ﬁrst-degree relatives, their fasting glucose < 126 mg/dl and BMI > 25. All the
participants provided written informed consent to participate in the study, the study
protocol was approved by Al-Quds University Research Ethics Committee (Rf no. 2/SRC/4).
Amplicon based next generation genotyping and bioinformatics
Genomic DNA was extracted from whole blood (300 ml) using genomic QIAamp DNA
puriﬁcation kit according to the manufacturer instructions (Qiagen, Hilden, Germany).
All DNA samples were genotyped for the T/C, rs2234693, and A/G, rs9340799, also
known as PvuII and XbaI polymorphisms, respectively using amplicon based next
generation sequencing (NGS). Brieﬂy, two primers (forward and reverse) were used to
target the two SNPs as previously described (Motawi et al., 2015). Both primers were
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modiﬁed with over hanged Illumina adaptor sequences at the 5′ ends (italic bolded,
Table S1) to target a partial sequence of 119 bp in length with a ﬁnal product of 186 bp
using conventional thermocycler.
The PCR product was visualized and captured on a 1.5% agarose gel, cleaned by
Agencourt AMPure XP system (X1, A63881; Beckman Coulter Genomics, Indianapolis,
IN, USA) and eluted in 25 ml elution buffer. All puriﬁed products were subjected to a
second round of ampliﬁcation to assign unique index sequences (barcode) for each
sample using Nextera XT Index Kit (Illumina, San Diego, CA, USA). Five ml from each
barcoded sample were pooled together, mixed and spin down. Then, 100 ml of the pooled
product was cleaned by Agencourt AMPure XP system (X1) (A63881; Beckman
Coulter Genomics), and eluted in 50 ml elution buffer. Library purity and quantity were
evaluated by 4200 TapeStation System (Agilent Technologies, Inc., Santa Clara, CA, USA)
using D1000 ScreenTape kit (Agilent Technologies, Inc., Santa Clara, CA, USA) and by
Qubit Fluorometer (Invitrogen, Carlsbad, CA, USA) using Qubit dsDNA high-sensitivity
assay (Invitrogen, Carlsbad, CA, USA). Concentration of four nM was prepared. 20 K
reads for each sample was targeted. Samples were deep sequenced on NextSeq 500/550
machine using the 150-cycle Mid Output Kit (Illumina, San Diego, CA, USA).
The obtained DNA sequences were uploaded on the Galaxy program (https://usegalaxy.
org/). Workﬂow of ﬁltration included Illumina adaptor trim, quality selection of Q > 20
with minimal read length of 100 bp. Four virtual probe sequences were used to identify
the PvuII and XbaI variants (Table S1). The genotypes were determined based on the
calculated ratio between the read counts for wild type and mutant alleles, for both
SNPs (PvuII and XbaI) in each individual sample.
Statistical analysis
Statistical analysis was performed with the SPSS package, version 19.0 (SPSS, Inc., Chicago,
IL, USA). All tests were two-tailed and P < 0.05 was considered signiﬁcant. The mean
values and standard errors were reported in tables. Genotype and allele frequencies in
T2DM and control subjects were tested by multivariable logistic regression analysis using
ﬁve genetic models: co-dominant, dominant, over-dominant, recessive and additive
with adjustment for age and BMI using R statistics (V 3.5.1; SNPassoc package)
(Gonzalez et al., 2007). The genotype frequencies were tested for Hardy–Weinberg
equilibrium by calculating a w2 statistic and corresponding P-value as previously described
by Mayo (2008). The risk to T2DM was estimated by computing odds ratios (ORs) and
95% conﬁdence intervals (CIs). Linkage disequilibrium (LD), coefﬁcient (D′) for haplotypes
and their frequencies were performed using R statistics (V 3.5.1; SNPassoc package)
(Gonzalez et al., 2007). Multivariate linear regression models taking into account age and
BMI were performed to assess associations between SNPs and T2DM complications.
All quantitative parameters were normalized before analysis using the “bestNormalize”
R package (https://github.com/petersonR/bestNormalize) (Peterson, 2017). To minimize
the chance of obtaining type I error, Bonferroni’s adjustment was applied. P < 0.025
was adopted as the signiﬁcant threshold unless otherwise speciﬁed. Quanto 1.2.4 software
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was used to estimate the statistical power (http://biostats.usc.edu/Quanto.html). The power
of any test of statistical signiﬁcance was <50%.
RESULTS
Biochemical and genetic analysis
Anthropometric and biochemical characteristics of study individuals are presented in
Table 1. In comparison with the control group, all clinical parameters showed statistically
signiﬁcant increase in T2DM patients (P < 0.05). However, no signiﬁcant difference in
diastolic blood pressure was observed among the two group (P = 0.4). The T2DM subjects
were signiﬁcantly older (P = 0.0001) but the control group were at the same mean age
at T2DM diagnosis in cases (P > 0.05) (Table 1). The cases had higher mean BMI
than control subjects but was at borderline signiﬁcance (P = 0.054). Among T2DM
patients, 10.8, 8.8, 7.8, and 5.9% had CVD, nephropathy, diabetic foot, and retinopathy,
respectively. The genotyping distribution for both variants was consistent with Hardy
Weinberg equilibrium in cases and control groups and in all subjects (P > 0.05).
Our results showed that the heterozygous genotypes TC and AG of the ESR1 PvuII and
XbaI polymorphisms were signiﬁcantly elevated in T2DM patients compared with control
individuals (P = 0.04, P = 0.01, respectively), while, the frequencies of C and G alleles
of the ESR1 PvuII and XbaI polymorphisms, respectively, were comparable among cases
and controls (P > 0.05) (Table 2). However, upon Bonferroni’s adjustment, only the
heterozygous genotype AG of the ESR1 XbaI remained signiﬁcantly higher in diabetic
group (P = 0.01).
PvuII and XbaI Polymorphisms in ESR1 gene and risk to type 2
diabetes
To estimate the effect of the genotypes on the disease, logistic regression analysis
was performed using ﬁve genetic models adjusted to age and BMI: additive, dominant,
codominant, recessive, and over-dominant. In the case of the PvuII T/C rs2234693
polymorphism, T2DM patients showed signiﬁcantly different genotypes distribution
compared to control group in three models, carriers of TC genotype had higher
risk to T2DM compared to those of TT genotype (OR = 2.84, CI [1.32–6.11]; P = 0.024)
Table 1 Demographic and biochemical characteristics of study subjects.
Control (n = 112) T2DM (n = 102) P-value
Age at sampling (years) 48.9 (0.68) 59.9 (0.95) 0.0001
Age at diagnosis (years) NA 49.6 (0.83)
BMI (Kg/m2) 32.5 (0.52) 34 (0.6) 0.054
SBP (mmHg) 122 (0.93) 136.2 (1.6) 0.0001
DBP (mmHg) 77.9 (0.85) 78.9 (1.02) 0.4
FBS (mg/dl) 90.1 (0.97) 161.8 (4.9) 0.0001
TC (mg/dl) 182 (3.4) 192 (4.02) 0.03
Notes:
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBS, fasting blood sugar.
Data are presented as mean (standard error); P < 0.05 was considered signiﬁcant (in bold). NA, Not applicable.
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Table 2 Allele frequencies and genotypes distribution of ESR1 gene PvuII and XbaI polymorphisms
in control and T2DM patients.
Allele/genotype All subjects (%) Control n (%) T2DM n (%) P-value
PvuII
T 244 (57) 133 (59) 111 (54) 0.46
C 184 (43) 91 (41) 93 (46) 0.46
TT 70 (33) 43 (38) 27 (26) 0.06
TC 104 (49) 47 (42) 57 (56) 0.04
CC 40 (19) 22 (20) 18 (18) 0.7
XbaI
A 247 (58) 132 (59) 115 (56) 0.6
G 118 (42) 92 (41) 89 (44) 0.7
AA 73 (34) 44 (39) 29 (28) 0.09
AG 101 (47) 44 (39) 57 (56) 0.01
GG 40 (19) 24 (21) 16 (16) 0.35
Notes:
Bold numbers showed the signiﬁcant correlation.
P-values lower than the Bonferroni threshold (P = 0.025) were considered statistically signiﬁcant.
Table 3 Association of ESR1 PvuI and XbaI variants with T2DM.
Model Genotype OR (95% CI) *P-value
PvuII SNP
Codominant T/T 1
T/C 2.84 [1.32–6.11] 0.024
C/C 1.77 [0.66–4.73]
Dominant T/T 1
T/C-C/C 2.50 [1.21–5.14] 0.011
Recessive T/T-T/C 1
C/C 0.96 [0.41–2.25] 0.92
Overdominant T/T-C/C 1
T/C 2.32 [1.18–4.55] 0.013
Log-additive – 1.48 [0.92–2.37] 0.1
Xba SNP
Codominant A/A 1
A/G 2.15 [1.02–4.51] 0.1
G/G 1.18 [0.45–3.10]
Dominant A/A 1
A/G-G/G 1.82 [0.91–3.66] 0.089
Recessive A/A-A/G 1
G/G 0.76 [0.32–1.80] 0.53
Overdominant A/A-G/G 1
A/G 2.03 [1.05–3.95] 0.035
Log-additive – 1.21 [0.76–1.92] 0.42
Note:
* P-values were from logistic regression models adjusted for age and BMI, P < 0.025 was considered signiﬁcant, bold
numbers showed the signiﬁcant correlation.
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(Table 3). In the dominant model, the TC+CC genotype carriers was signiﬁcantly at
higher risk to T2DM than TT genotypes (OR = 2.50, CI [1.21–5.14]; P = 0·011).
In the over-dominant model (TT+CC vs. TC), the association was also signiﬁcant
(OR = 2.32, CI [1.18–4.55]; P = 0.013) (Table 3). The analysis of the Xba rs9340799 A/G
polymorphism showed a trend for association with T2DM in the over dominant model
(AA+GG vs. AG) (OR = 2.03, CI [1.05–3.95]; P = 0.035) (Table 3).
Biochemical characteristics of T2DM individuals according to ESR1 PvuII and
XbaI genotypes are shown in Table 4. It demonstrated insigniﬁcant association of
the investigated parameters across genotypes of both polymorphisms (P > 0.05).
A stratiﬁed analysis of combined genotypes with respect to different genetic models
also revealed no signiﬁcant association with any biochemical or clinical parameter
(data not shown).
LD estimation between ESR1 SNPs and haplotype analysis
The polymorphisms tested were in LD (normalized Lewontin’s D′ = 0.91). Among all
subjects, the most common haplotype, TA, had a frequency of 55%, and the CG haplotype
had a frequency of 40% while two haplotypes CA and TG had frequencies of 2.9% and
2.2%, respectively. The frequencies of the four haplotypes were not signiﬁcantly different
in the T2DM patients compared with control group as shown in Table 5. In logistic
Table 4 Demographic characteristics and biochemical measurements based on ESR1 PvuII and XbaI genotypes in diabetic women.
Parameter PvuII genotypes XbaI genotypes
CC TC TT P-value AA AG GG P-value
BMI (Kg/m2) 34.5 (1.8) 33.7 (0.69) 34.1 (1.3) 0.91 34.5 (1.24) 33.5 (0.69) 34.8 (1.9) 0.67
SBP (mmHg) 143.5 (3.50) 135.5 (2.2) 133 (2.9) 0.09 134.6 (2.75) 135.3 (2.27) 142.4 (3.8) 0.25
DBP (mmHg) 79 (3.0) 78.8 (1.4) 78.7 (1.6) 0.93 79.9 (1.65) 78.5 (1.4) 78.1 (3.1) 0.79
FBS (mg/dl) 169.85 (13.2) 162.82 (6.84) 154.44 (8.1) 0.59 159.24 (9.39) 159.14 (6.36) 176.21 (13.98) 0.46
HbA1C 8.28 (0.47) 7.86 (0.26) 7.72 (0.38) 0.62 7.83 (0.4) 7.78 (0.24) 8.46 (0.52) 0.46
TC (mg/dl) 202.42 (11.68) 188.29 (5.3) 192.33 (7.39) 0.45 191.52 (6.84) 189.57 (5.59) 200.6 (11.78) 0.65
TG (mg/dl) 250.07 (62.75) 192.87 (19.25) 164.45 (6.84) 0.2 164.9 (6.37) 212.01 (27.22) 191.75 (15.81) 0.42
LDL (mg/dl) 118.3 (7.69) 105.95 (3.29) 105.59 (4.78) 0.19 106.1 (4.47) 106.57 (3.53) 116.78 (7.48) 0.36
HDL (mg/dl) 38.56 (2.8) 41.58 (1.19) 44.55 (1.62) 0.11 44.38 (1.59) 41.14 (1.2) 39.69 (3.04) 0.2
Notes:
TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
Values are presented as mean (standard error); P-value was obtained by ANOVA, P < 0.05 was considered signiﬁcant.
Table 5 Estimated haplotype distributions in cases (T2DM) and control groups.
PvuII XbaI Frequency
(case)
Frequency
(control)
Frequency
(total)
OR (95% CI) P-value Global P
T A 0.5391 0.557 0.5485 1 – 0.14
C G 0.4312 0.374 0.4013 1.36 [0.84–2.21] 0.21
C A 0.0247 0.0323 0.0286 2.28 [0.62–8.37] 0.22
T G 0.005 0.0367 0.0216 0.21 [0.02–2.66] 0.23
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regression analyses, adjusting for the same potential confounders (age and BMI) used in
the genotype models, none of the four possible haplotypes were associated with increased
risk of diabetes (global P = 0.14) (Table 5).
Association of ESR1 PvuII and XbaI Polymorphisms with CVD in
diabetic group
The association of PvuII and XbaI SNPs within the ESR1 gene and CVD risk was evaluated
among diabetic group (n = 102) using logestic regression after adjustment of age and BMI.
Under the dominant model, the combined PvuII TC+CC genotypes have a trend to
lower risk of CVD compared with TT genotype (OR = 0.25, CI [0.07–0.93]; P = 0.039).
A similar trend was observed in the combined genotypes (AG+GG) of the ESR1 XbaI
compared to AA (OR = 0.26, CI [0.07–0.99]; P = 0.049) as shown in Table 6. The frequency
of CG haplotype was statistically higher in diabetic patients without CVD (46%) compared
to those with CVD (23%) (OR = 0.28, CI [0.09–0.90]; adjusted P = 0.035). On the
other hand, we did not ﬁnd any association of ESR1 PvuII and XbaI polymorphisms with
the other T2DM complications including nephropathy, retinopathy, and diabetic foot
(data not shown).
Table 6 Association of ESR1 PvuII and XbaI variants with CVD among T2DM cases.
PvuII SNP CVD
Model Genotype Yes (%) No (%) OR (95% CI) P-value
Dominant T/T 54.5 23.1 1
T/C-C/C 45.5 76.9 0.25 [0.07–0.93] 0.039
Recessive T/T-T/C 90.9 81.3 1
C/C 9.1 18.7 0.41 [0.05–3.57] 0.36
Overdominant T/T-C/C 63.6 41.8 1
T/C 36.4 58.2 0.42 [0.11–1.57] 0.19
Xba SNP CVD
Model Genotype Yes (%) No (%) OR (95% CI) P-value
Dominant A/A 54.5 25.3 1
A/G-G/G 45.5 74.7 0.26 [0.07–0.99] 0.049
Recessive A/A-A/G 100 82.4 1
G/G 0 17.6 0.00 [0.00–NA] 0.036
Overdominant A/A-G/G 54.5 42.9 1
A/G 45.5 57.1 0.64 [0.18–2.31] 0.49
PvuII/XbaI CVD
Haplotype Yes (%) No (%) OR (95% CI) P-value
T/A 73 52 1
C/G 23 46 0.28 [0.09–0.90] 0.035
C/A 4 2 2.75 [0.22–33.96] 0.43
Note:
NA, not applicable.
Ereqat et al. (2019), PeerJ, DOI 10.7717/peerj.7164 8/15
DISCUSSION
The prevalence of diabetes has increased worldwide, most markedly in the world’s
middle-income countries which reﬂects an increase in associated risk factors such as
being overweight or obese (World Health Organization (WHO), 2016). At menopause,
women experience health challenges due to estrogen deﬁciency. The risk of T2DM is
increasing with post-menopause status interacting with other risk factors, that is,
hypertension, dyslipidemia, and obesity (Ren et al., 2018). Estrogen may regulate insulin
action directly via actions on insulin-sensitive tissues. In skeletal muscle, ESR1 is thought
to have a positive effect on insulin signaling and GLUT4 expression. It has been shown
that stimulation of estrogen receptor with its agonist propylpyrazoletriyl increased
insulin-stimulated glucose uptake in skeletal muscles (Gorres et al., 2011). Although not all
studies are in agreement, PvuII and XbaI and other polymorphisms across the ESR1 gene
have been associated with risk of T2DM as reported in the Chinese (Huang et al.,
2006), African–Americans, European–Americans (Sale et al., 2004), Hungarians (Speer
et al., 2001), and Egyptian women (Motawi et al., 2015). In this study, the frequency for
ESR1 PvuII and XbaI alleles and genotypes in Palestinian women (n = 214) was evaluated.
Our results reported that the ESR1 PvuII C and XbaI G allele frequencies were similar
to other studies among Arab population (El-Beshbishy et al., 2015; Motawi et al., 2015).
However, several studies showed distinct prevalence for these two polymorphisms,
particularly the XbaI alleles (Ganasyam et al., 2012). Discrepancies in allelic frequencies
between reports may be attributed to the ethnic variability of the studied populations,
heterogeneity of the analyzed diseases and sample size.
Most often, deviation from the Hardy–Weinberg equilibrium (HWE) is caused by a
small sample size and poor genotyping quality. In this study, minimization of
genotyping errors was achieved by amplicon based NGS, It provides a lower cost per
sample alternative to restriction fragment length polymorphism (RFLP), probe based
Taq-man PCR and Sanger sequencing. RFLP, a traditional genotyping method, requires a
high quality, and quantity of DNA sample and numerous steps including ampliﬁcation,
digestion with restriction enzymes and gel electrophoresis which can be a laborious and
time-consuming process. Moreover, conﬁrmatory sequencing must be performed when a
sample shows confused banding pattern particularly the bands of low molecular size. In our
analysis, DNA sequences with a quality score of more than 20 (>Q20), Q20 represents an
error rate of 1 in 100 with a corresponding call accuracy of 99%, were selected. Amplicon
based NGS requires advanced instrumentation, however and despite this limitation, we
believe that it is the method of choice for genotyping studies and for rapid genetic screening
of several hundred to thousands of samples.
To our knowledge, this is the ﬁrst report to investigate whether ESR1 PvuII and
XbaI alleles and their genotypes and haplotypes are associated with T2DM among
Palestinian women.
In this study, the additive, dominant, co dominant, and recessive genotypic models
of association were tested, all were adjusted for age and BMI. The ESR1 PvuII variant,
supported evidence for association with risk of T2DM in three genotypic models
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(P < 0.025) but the strongest association was observed in the overdominant model,
in which heterozygous carries confer a higher risk compared to homozygotes (Table 3).
Although such association toward the heterozygotes could result from genotyping error,
this is unlikely to be the case in our study as we used variant speciﬁc probes as
described above.
One possible explanation is that the variant allele may have a very strong dominant
effect so that there is little difference between the effects of the variant homozygotes
and heterozygotes. Given that the majority of participants in both cases and controls
were heterozygotes, the real effect among the variant homozygotes can only be assessed
by much larger study in the future. On the other hand, the over dominant model
(upon Bonferroni correction) showed a trend for association of XbaI SNP with T2DM
(OR = 2.03, CI [1.05–3.95], P = 0.035) which was unexpected given the tight LD between
these two polymorphisms. These results could also be attributed to the poor statistical
power due to small sample size. Considering the associations of both SNPs found in other
studies, we believe that further study involving a larger number of participants is needed
to elucidate the exact role of these polymorphisms in susceptibility to T2DM. However,
in 2018, a meta-analysis including eight studies indicated that PvuII, rather than XbaI
polymorphism, was associated with T2DM (OR = 0.673, 95% CI [0.550–0.823]). In that
study, the C allele of PvuII polymorphism showed a protective role in T2DM in Chinese
people while the G allele of XbaI polymorphism is related to a reduced risk for T2DM
in Caucasian population (Yang et al., 2018). Thus, we believe that physiological pathway
to diabetes may vary among different population and those differences are reﬂected in
part by genetic differences. Therefore, the results of our study should be considered
exploratory and conﬁrmed by additional studies including other polymorphisms/genes
as one single gene polymorphisms are not enough to answer the pathogenesis of a complex
disease such as T2DM. Further, it is well known that estrogens regulate the cardiovascular
system via their direct effects on the vessel wall and indirect effects on total cholesterol
and triglycerides metabolism (Liping et al., 2013). Among diabetic group, stratiﬁed
analyses based on ESR1 PvuII and XbaI genotypes revealed no evidence for association
with lipid levels (TC, TG, HDL, LDL). Moreover, we did not ﬁnd any association
between the two polymorphisms (PvuII and XbaI) and TC in control group (n = 114).
One limitation of this study is the lack of information about subjects who received
hormone replacement therapy and/or lipid lowering agent which may affect their serum
lipid proﬁle, therefore, we were unable to study the interaction between these variants and
hormone replacement therapy on lipid proﬁle which was, however, beyond the scope
of this study. It is reported that the effect of PvuII and XbaI polymorphisms on serum
lipids depend on several other genes not on ESR1 gene alone. Similarly, Matsubara
et al. (1997) and Almeida et al. (2006) did not ﬁnd any association between the two
polymorphisms and serum lipid proﬁle in post-menopausal women (Almeida et al., 2006;
Matsubara et al., 1997). A recent study conducted on a cohort of post-menopausal
Brazilian women reported no effects of PvuII SNP of ESR1 gene on patient’s serum TC,
LDL, HDL, and TG, while XbaI SNP was associated to changes in TG and total lipids
mainly in obese and overweight woman (Gomes-Rochette et al., 2017). In contrast,
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Egyptian study showed that both PvuII and XbaI SNPs have been associated with increased
levels of triglycerides, total cholesterol, and LDL (Motawi et al., 2015).
The mechanism by which intronic polymorphisms of ESR1 gene might confer increased
risk of T2DM is not fully understood. However, it is reported that the PvuII and XbaI
polymorphisms change the ESR1 gene expression by altering the binding of its own
transcription factors. Moreover, LD between these two polymorphisms with other
polymorphisms in the ESR1 gene, such as TA tandem polymorphism in the promoter
region could affect gene expression or function (Herrington et al., 2002). Polymorphisms
in ESR1 were ﬁrst thought to be potential risk factors for the development of CVD, but
a meta-analysis including 10 case-control studies demonstrated that the ESR1 SNPs
PvuII and XbaI are not associated with risk of CVD (Morselli et al., 2017). In this study
we have noted an inverse trend between these polymorphisms and risk of CVD in diabetic
group. Our ﬁndings cannot be a deﬁnitive conclusion to identify ESR1 genotype/haplotype
that could be useful in identiﬁcation of diabetic women that are more prone to develop
CVD due to small sample size with limited statistical power to detect interactions or perform
subgroups analyses which was the most obvious limitation of this study.
CONCLUSIONS
The present study suggests that the PvuII polymorphism in the ESR1 gene is associated
with increased risk of type 2 diabetes but not with lipid proﬁle. The interaction between
XbaI genotype and T2DM still need to be clariﬁed. Identiﬁcation of genetic risk markers
can be used in deﬁning high risk subjects and in prevention trials. The mechanism by
which the ESR1 PvuII and XbaI polymorphisms might be related to CVD-among diabetic
group-needs further investigation with larger sample size. Also, future studies are
warranted to replicate our results and to explain the inﬂuence of these intronic
polymorphisms on diabetes susceptibility in Palestine.
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